Highly sensitive immunoassay for human cardiac troponin based
on photon-upconversion nanoparticles

BRANDMEIER, Julian, Kirsti RAIKO, Zdeněk FARKA, Riikka PELTOMAA, Matthias Jürgen MICKERT, Antonín HLAVÁČEK, Petr SKLÁDAL, Tero SOUKKA and Hans-Heiner GORRIS. Highly sensitive immunoassay for human cardiac troponin based on photon-upconversion nanoparticles. In UPCONline 2021. 2021.

Other formats: BibTeX LaTeX RIS

TY  - CONF
ID  - 1757239
AU  - Brandmeier, Julian - Raiko, Kirsti - Farka, Zdeněk - Peltomaa, Riikka - Mickert, Matthias Jürgen - Hlaváček, Antonín - Skládal, Petr - Soukka, Tero - Gorris, Hans-Heiner
PY  - 2021
TI  - Highly sensitive immunoassay for human cardiac troponin based on photon-upconversion nanoparticles
N2  - With 15.2 million deaths in 2016 and a rising trend, more people die annually suffering a heart attack than from any other cause or disease. There is only a limited time available from the onset of the symptoms of acute myocardial infarction (AMI) to lifesaving treatment. Cardiac troponin is the recommended marker in the early AMI diagnosis. The standard assays are based on electrochemiluminescence, chemiluminescence, or electrochemical detection. Even though reaching acceptable limits of detection (LOD), higher sensitivity is still necessary. To overcome the performance of current methods, we designed streptavidin-modified photon upconversion nanoparticles (SA-UCNP) based on a PEG linker and utilized them in upconversion immunoassays to detect cardiac troponin. We developed two assays; a microtiter plate-based upconversion immunoassay (ULISA) for sensitive laboratory diagnosis and a lateral-flow immunoassay (LFIA) for rapid detection. The PEG linker allowed reducing the non-specific interactions due to the steric hindrance and repulsion effects. For the ULISA, we chose a 2+2 assay configuration, with two monoclonal antibodies coated on the surface to capture the analyte, which was then detected by two biotinylated antibodies and SA-UCNPs. The LFIA was based on a 2+1 configuration, with one biotinylated antibody for the detection; biotinylated BSA was used for the control line. We achieved LOD of 4.7 pg/mL for the ULISA and 13.8 ng/mL for LFIA, respectively. Furthermore, we demonstrated that the ULISA is a feasible alternative to existing assays, with LOD in the serum of 15.5 pg/mL, two times lower than the troponin concentration in healthy patients.
ER  -

Basic information
Original name	Highly sensitive immunoassay for human cardiac troponin based on photon-upconversion nanoparticles
Authors	BRANDMEIER, Julian, Kirsti RAIKO, Zdeněk FARKA, Riikka PELTOMAA, Matthias Jürgen MICKERT, Antonín HLAVÁČEK, Petr SKLÁDAL, Tero SOUKKA and Hans-Heiner GORRIS.
Edition	UPCONline 2021, 2021.

Other information
Original language	English
Type of outcome	Conference abstract
Field of Study	10406 Analytical chemistry
Country of publisher	France
Confidentiality degree	is not subject to a state or trade secret
Organization unit	Faculty of Science
Tags	International impact
Changed by	Changed by: doc. Mgr. Zdeněk Farka, Ph.D., učo 357740. Changed: 10/5/2021 22:48.

Abstract

With 15.2 million deaths in 2016 and a rising trend, more people die annually suffering a heart attack than from any other cause or disease. There is only a limited time available from the onset of the symptoms of acute myocardial infarction (AMI) to lifesaving treatment. Cardiac troponin is the recommended marker in the early AMI diagnosis. The standard assays are based on electrochemiluminescence, chemiluminescence, or electrochemical detection. Even though reaching acceptable limits of detection (LOD), higher sensitivity is still necessary. To overcome the performance of current methods, we designed streptavidin-modified photon upconversion nanoparticles (SA-UCNP) based on a PEG linker and utilized them in upconversion immunoassays to detect cardiac troponin. We developed two assays; a microtiter plate-based upconversion immunoassay (ULISA) for sensitive laboratory diagnosis and a lateral-flow immunoassay (LFIA) for rapid detection. The PEG linker allowed reducing the non-specific interactions due to the steric hindrance and repulsion effects. For the ULISA, we chose a 2+2 assay configuration, with two monoclonal antibodies coated on the surface to capture the analyte, which was then detected by two biotinylated antibodies and SA-UCNPs. The LFIA was based on a 2+1 configuration, with one biotinylated antibody for the detection; biotinylated BSA was used for the control line. We achieved LOD of 4.7 pg/mL for the ULISA and 13.8 ng/mL for LFIA, respectively. Furthermore, we demonstrated that the ULISA is a feasible alternative to existing assays, with LOD in the serum of 15.5 pg/mL, two times lower than the troponin concentration in healthy patients.

Links
LQ1601, research and development project	Name: CEITEC 2020 (Acronym: CEITEC2020)
LQ1601, research and development project	Investor: Ministry of Education, Youth and Sports of the CR
LTAB19011, research and development project	Name: Luminiscenční imunostanovení jako citlivý nástroj pro diagnostiku nemocí včel
LTAB19011, research and development project	Investor: Ministry of Education, Youth and Sports of the CR, Sensitive bioanalytical tools for the surveillance of honey bee diseases, INTER-ACTION

PrintDisplayed: 31/7/2024 00:25

Highly sensitive immunoassay for human cardiac troponin based on photon-upconversion nanoparticles

Other applications